Cabozantinib is a new biological treatment called a tyrosine kinase inhibitor or TKI. It stops signals that cancer cells use to divide and grow. It is currently being considered as a treatment option for patients who fail primary treatment with sorafenib.
Cabozantinib for Hepatocellular Carcinoma
Interventions: Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)
Indications: Hepatocellular carcinoma (HCC)
Therapeutic Areas: Gastrointestinal Cancer